PGR (Progesterone receptor)

P=N/A, N=186, Not yet recruiting, Federico II University

Conclusions In this retrospective, single-center study, 58.8% of patients with a positive SLN had additional axillary metastases following completion ALND, underscoring that residual nodal disease remains common and clinically significant. Conversely, 41.2% had no further axillary involvement, consistent with literature supporting selective de-escalation of axillary surgery in carefully selected patients.

Routine radiological staging investigation is advocated for invasive LRR. Majority of LRR were resectable, with nodal positivity rate comparable to the original cancer.

P2, N=27, Recruiting, Xijing Hospital | Trial primary completion date: Apr 2026 --> Dec 2026

P2, N=40, Recruiting, University of Illinois at Chicago | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

P1, N=27, Active, not recruiting, Institut Paoli-Calmettes | Recruiting --> Active, not recruiting

Despite the initiation of corticosteroids and methotrexate, the patient showed clinical deterioration over four weeks...Following neoadjuvant chemotherapy, surgery, and radiation, the patient achieved complete remission of her myositis, with normalisation of creatine phosphokinase (CPK) levels, resolution of rash, and recovery of muscle strength, confirming the paraneoplastic aetiology. This case underscores the imperative to pursue malignancy screening in DM patients unresponsive to immunosuppressive therapy, regardless of age. It highlights the critical role of thorough physical examination and the superiority of breast imaging in young women with dense breasts.

Adjuvant therapy comprised paclitaxel (175 mg/m²) plus cisplatin (75 mg/m²) every 3 weeks for six cycles, combined with pembrolizumab (200 mg every 3 weeks). To our knowledge, this is one of the first reported cases of pembrolizumab combined with platinum-based chemotherapy in the adjuvant setting for primary triple-negative NEBC. This case provides hypothesis-generating evidence for chemo-immunotherapy in this rare, high-grade histologic subtype.

Grade 3 histology further worsens the prognosis. Traditional pathological markers continue to be critical for individualized risk assessment and treatment planning.

Receptor discordance between primary tumors and nodal metastases is common, with most shifts occurring within the HER2-spectrum. There was a trend toward higher RS and ER or HER2-receptor discordance. HER2 discordance was also associated with larger tumor size and larger size of nodal metastasis. As strategies emerge to target HER2-low cohorts and to include ER-low/HER2-negative disease within treatment regimens for TNBC, it may become important to consider receptor testing of nodal disease in the future.

In this exploratory cohort, baseline progesterone receptor expression patterns were associated with response to progestin-based therapy. These findings warrant validation in larger, prospective studies.

PR-related gene expression (PGR, FOXO1, and CYP26A1) did not differ between adenomyosis groups. Although preliminary, the present findings indicate that adenomyosis coexisting with EC is characterized by elevated expression of ESR2 and BRCA1, suggesting an enriched ER-related microenvironment that may be relevant to local estrogen responsiveness.